Onconova Therapeutics, Inc. (ONTX) Analysts See $-0.08 EPS

July 14, 2018 - By Elizabeth Bryant

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Logo

Analysts expect Onconova Therapeutics, Inc. (NASDAQ:ONTX) to report $-0.08 EPS on August, 13.They anticipate $0.21 EPS change or 72.41 % from last quarter’s $-0.29 EPS. After having $-0.34 EPS previously, Onconova Therapeutics, Inc.’s analysts see -76.47 % EPS growth. The stock 1.07% or $0 during the last trading session, reaching $0.45. It is down 81.06% since July 14, 2017 and is downtrending. It has underperformed by 93.63% the S&P500.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Ratings Coverage

Among 2 analysts covering Onconova Therapeutics (NASDAQ:ONTX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Onconova Therapeutics had 8 analyst reports since January 17, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, May 15 by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $7.5 target in Friday, March 9 report. Maxim Group downgraded the shares of ONTX in report on Wednesday, January 17 to “Hold” rating. H.C. Wainwright maintained it with “Buy” rating and $6.0 target in Thursday, January 18 report. The company was maintained on Thursday, March 1 by H.C. Wainwright. The stock of Onconova Therapeutics, Inc. (NASDAQ:ONTX) earned “Buy” rating by Maxim Group on Wednesday, May 2. The rating was downgraded by Maxim Group on Wednesday, January 31 to “Hold”. The stock of Onconova Therapeutics, Inc. (NASDAQ:ONTX) earned “Buy” rating by H.C. Wainwright on Monday, March 26.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company has market cap of $35.22 million. The company's clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes ; Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes.

Another recent and important Onconova Therapeutics, Inc. (NASDAQ:ONTX) news was published by Globenewswire.com which published an article titled: “Onconova Therapeutics Announces Promotion for Steven M. Fruchtman, MD” on June 21, 2018.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.